Targeted proteomics: A bridge between discovery and validation

Expert Review of Proteomics

Volumn 11, Issue 6, 2014, Pages 657-661

  Harlan, Robert ^a   Zhang, Hui ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; LCMS; MRM, PRM; proteomics; SRM; targeted proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS SPECTROMETRY; MONITORING; PROTEOMICS; SELECTED REACTION MONITORING; MEDICAL RESEARCH; PROCEDURES;

BIOMARKERS; BIOMEDICAL RESEARCH; HUMANS; MASS SPECTROMETRY; PROTEINS; PROTEOMICS;

EID: 84910620579     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.976558     Document Type: Article

References (68)

1. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422(6928):198-207
2. Domon B, Aebersold R Mass spectrometry and protein analysis. Science 2006; 312(5771):212-17
3. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56(2): 177-85
4. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 2012;9(6):555-66
5. Huttenhain R, Surinova S, Ossola R, et al. N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol Cell Proteomics 2013;12(4):1005-16
6. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24(8):971-83
7. Surinova S, Schiess R, Huttenhain R, et al. On the development of plasma protein biomarkers. J Proteome Res 2011;10(1): 5-16
8. Skates SJ, Gillette MA, Labaer J, et al. Statistical Design for Biospecimen Cohort Size in Proteomics-based Biomarker Discovery and Verification Studies. J Proteome Res 2013;12(12):5383-94
9. Percy AJ, Chambers AG, Parker CE, Borchers C.H. Absolute quantitation of proteins in human blood by multiplexed multiple reaction monitoring mass spectrometry. Methods Mol Biol 2013;1000:167-89
10. Whiteaker JR, Lin C, Kennedy J, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 2011;29(7):625-34
11. Stoop MP, Singh V, Stingl C, et al. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res 2013; 12(3):1101-7
12. Shi T, Gao Y, Quek SI, et al. A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J Proteome Res 2014;13(2):875-82
13. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 2009;3(1): 33-44
14. Cima I, Schiess R, Wild P, et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA 2011;108(8):3342-7
15. Cerciello F, Choi M, Nicastri A, et al. Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clin Proteomics 2013; 10(1):16
16. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5(4):573-88
17. Kuhn E, Wu J, Karl J, et al. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004;4(4):1175-86
18. Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009; 138(4):795-806
19. Harlan R, Clarke W, Di Bussolo JM, et al. An automated turbulent flow liquid chromatography-isotope dilution mass spectrometry (LC-IDMS) method for quantitation of serum creatinine. Clin Chim Acta 2010;411(21-22):1728-34
20. Boutin JA, Ernould AP, Ferry G, et al. Use of hydrophilic interaction chromatography for the study of tyrosine protein kinase specificity. J Chromatogr 1992;583(2): 137-43
21. Alpert AJ. Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J Chromatogr 1990;499: 177-96
22. Yost RA, Enke CG. Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation. Anal Chem 1979; 51(12):1251-64
23. Kleinschnitz M, Herderich M, Schreier P. Determination of 1, 4-benzodiazepines by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Appl 1996;676(1):61-7
24. Gutsche B, Herderich M. High-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry for the analysis of 1, 2, 3, 4-tetrahydro-beta-carboline derivatives. J Chromatogr A 1997;767(1-2): 101-6
25. Zell M, Husser C, Hopfgartner G. Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma. J Mass Spectrom 1997;32(1):23-32
26. Tretyakova N, Chiang SY, Walker VE, Swenberg JA. Quantitative analysis of 1, 3-butadiene-induced DNA adducts in vivo and in vitro using liquid chromatography electrospray ionization tandem mass spectrometry. J Mass Spectrom 1998;33(4): 363-76
27. Elschenbroich S, Kislinger T. Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery. Mol Biosyst 2011;7(2):292-303
28. Halquist MS, Thomas Karnes H. Quantitative liquid chromatography tandem mass spectrometry analysis of macromolecules using signature peptides in biological fluids. Biomed Chromatogr 2011; 25(1-2):47-58
29. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J Mass Spectrom 2011;46(3):298-312
30. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27(7): 633-41
31. Prakash A, Rezai T, Krastins B, et al. Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res 2012;11(8):3986-95
32. Prakash A, Rezai T, Krastins B, et al. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res 2010;9(12):6678-88
33. Ravanat JL, Duretz B, Guiller A, et al. Isotope dilution high-performance liquid chromatography-electrospray tandem mass spectrometry assay for the measurement of 8-oxo-7, 8-dihydro-2'-deoxyguanosine in biological samples. J Chromatogr B Biomed Sci Appl 1998;715(2):349-56
34. Zhang H, Henion J. Comparison between liquid chromatography-time of-flight mass spectrometry and selected reaction monitoring liquid chromatography-mass spectrometry for quantitative determination of idoxifene in human plasma. J Chromatogr B Biomed Sci Appl 2001; 757(1):151-9
35. Yang L, Amad M, Winnik WM, et al. Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays. Rapid Commun Mass Spectrom 2002;16(21): 2060-6
36. Hughes N, Winnik W, Dunyach JJ, et al. High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities. J Mass Spectrom 2003;38(7):743-51
37. You Y, Uboh CE, Soma LR, et al. Validated UHPLC-MS-MS method for rapid analysis of capsaicin and dihydrocapsaicin in equine plasma for doping control. J Anal Toxicol 2013;37(2): 122-32
38. Xiong X, Yang L, Duan J. Development and validation of a sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of quetiapine and its active metabolite norquetiapine in human plasma. Clin Chim Acta 2013;423: 69-74
39. Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002;1(5):376-86
40. Mayya V, Rezual K, Wu L, et al. Absolute quantification of multisite phosphorylation by selective reaction monitoring mass spectrometry: determination of inhibitory phosphorylation status of cyclin-dependent kinases. Mol Cell Proteomics 2006;5(6): 1146-57
41. Fortin T, Salvador A, Charrier JP, et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009;8(5):1006-15
42. Stahl-Zeng J, Lange V, Ossola R, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007; 6(10): 1809-17
43. Whiteaker JR, Zhao L, Zhang HY, et al. Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 2007;362(1):44-54
44. Wang P, Whiteaker JR, Paulovich AG. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009;8(12): 1083-94
45. Ebhardt HA. Selected reaction monitoring mass spectrometry: a methodology overview. Methods Mol Biol 2014;1072:209-22
46. Bertsch A, Jung S, Zerck A, et al. Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics. J Proteome Res 2010;9(5): 2696-704
47. Kennedy JJ, Abbatiello SE, Kim K, et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods 2014;11(2): 149-55
48. Nanjappa V, Thomas JK, Marimuthu A, et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res 2014;42(1): D959-65
49. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 2005;173(10): 1191-202
50. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140(6):917-27
51. Kasimir-Bauer S. Circulating tumor cells as markers for cancer risk assessment and treatment monitoring. Mol Diagn Ther 2009;13(4):209-15
52. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008;2(10-11):1386-402
53. Chen J, Shah P, Zhang H. Solid phase extraction of N-linked glycopeptides using hydrazide tip. Anal Chem 2013;85(22): 10670-4
54. Rost H, Malmstrom L, Aebersold R. A computational tool to detect and avoid redundancy in selected reaction monitoring. Mol Cell Proteomics 2012;11(8):540-9
55. Farrah T, Deutsch EW, Kreisberg R, et al. PASSEL: the PeptideAtlas SRMexperiment library. Proteomics 2012;12(8):1170-5
56. Gallien S, Bourmaud A, Kim SY, Domon B. Technical considerations for large-scale parallel reaction monitoring analysis. J Proteomics 2014;100:147-59
57. DeSouza LV, Taylor AM, Li W, et al. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal endometrial tissues. J Proteome Res 2008;7(8):3525-34
58. DeSouza LV, Romaschin AD, Colgan TJ, Siu KW. Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer. Anal Chem 2009;81(9):3462-70
59. Byers HL, Campbell J, van Ulsen P, et al. Candidate verification of iron-regulated Neisseria meningitidis proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring. J Proteomics 2009;73(2):231-9
60. Kim JS, Fillmore TL, Liu T, et al. 18O-labeled proteome reference as global internal standards for targeted quantification by selected reaction monitoring-mass spectrometry. Mol Cell Proteomics 2011; 10(12):M110.007302
61. Yao X, Freas A, Ramirez J, et al. Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus. Anal Chem 2001;73(13): 2836-42
62. Aye TT, Low TY, Bjorlykke Y, et al. Use of stable isotope dimethyl labeling coupled to selected reaction monitoring to enhance throughput by multiplexing relative quantitation of targeted proteins. Anal Chem 2012;84(11):4999-5006
63. Mirzaei H, Brusniak MY, Mueller LN, et al. Halogenated peptides as internal standards (H-PINS): introduction of an MS-based internal standard set for liquid chromatography-mass spectrometry. Mol Cell Proteomics 2009;8(8):1934-46
64. Escher C, Reiter L, MacLean B, et al. Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 2012;12(8):1111-21
65. Chindarkar NS, Wakefield MR, Stone JA, Fitzgerald RL. Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening. Clin Chem 2014;60:1115-25
66. Liu Y, Chen J, Sethi A, et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics 2014;13(7):1753-68
67. Prakash A, Rezai T, Krastins B, et al. Inter-laboratory reproducibility of SRM assays using multiple upfront analyte enrichment strategies. J Proteome Res 2012;11:3986-95
68. Anderson NL, Anderson NG, Haines LR, et al. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004;3(2):235-44